BioCentury
ARTICLE | Product Development

Round trip for Seres following Phase II UC miss

Microbiome play to move ahead with next-gen UC program SER-301

July 22, 2021 11:35 PM UTC

Seres is moving ahead with its next-in-line ulcerative colitis program SEC-301 following a Phase IIb failure for its lead UC candidate SER-287 that erased $1.2 billion from the microbiome company’s market cap. 

On Thursday,  Seres Therapeutics Inc. (NASDAQ:MCRB) fell $12.88 (62%) to $7.95 after SER-287 missed its primary endpoint of improving clinical remission rates vs. placebo in the Phase IIb ECO-RESET study in patients with mild-to-moderate UC. The company has terminated the open-label and maintenance portions of the study...

BCIQ Company Profiles

Seres Therapeutics Inc.